Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class ASSE: 688505

Report for Q1 2026

Apr 30, 2026 · Issued by Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange

Report for Q1 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Earlier from Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood ConferenceApr 29
Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of FZ-P001 Sodium for Injection for Visualization of Malignant Lesions during Ovarian Cancer SurgeryApr 10
Announcement on Requesting the General Meeting to Authorize the Board of Directors to Issue Shares to Specific Objects by Summary ProcedureMar 31
Announcement on Preliminary Earnings Estimate for 2025Feb 28

All Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A news releases